A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

BACKGROUND: Ustekinumab (UST), a monoclonal antibody to IL-12 and 23, was recently approved for the treatment of moderate-severe CD. AIMS: Here we report safety data with and without concomitant use of Immunomodulators(IMM) and corticosteroids(CS) in induction and maintenance in pts pooled from the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Can Assoc Gastroenterol
Hlavní autoři: Sands, B E, Gasink, C, Jacobstein, D, Ott, E, Lang, Y, Ramachandran, P, Ghosh, S
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Paper Sessions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508235/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky